MedTrace Logo

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC

NCT05332496 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 941

Last updated 2026-04-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with PD-1/PD-L1 Inhibitors and molecular target therapies in patients with Intermediate-stage hepatocellular carcinoma (HCC).

Conditions

Interventions

DRUG

PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab

PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.

PROCEDURE

TACE

TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);

Sponsors & Collaborators

  • Zhongda Hospital

    lead OTHER

Principal Investigators

  • Gao-Jun Teng, M.D. · Zhongda hospital, Southeast university, Nanjing, China

  • Zheng-Gang Ren, M.D. · Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-28
Primary Completion
2023-07-30
Completion
2025-09-14

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05332496 on ClinicalTrials.gov